Search

everythinglearnresearchcommunity

for

Search:↓

Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.

Topical melatonin, caffeine, and adenosine have shown impressive results in increasing hair density by 55% in 8 weeks, according to a Medium article.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

A user is seeking a UK source for a combined minoxidil and RU58841 solution that doesn't contain scalp-irritating ingredients. They specifically want a product without propylene glycol (PG).

Dutasteride is praised for improving skin and hair regrowth, with fewer side effects than finasteride. Users report mixed results on shedding and regrowth, with some experiencing enhanced libido and skin quality.

The user has been using 2.5mg oral minoxidil for almost 9 months with reduced shedding but no regrowth and is considering adding oral finasteride despite potential side effects. They plan to consult their dermatologist about this addition to their treatment.

The conversation discusses the safety and effectiveness of continuing or adding RU58841 after stopping finasteride for hair loss treatment. One user expresses skepticism about using RU58841 due to the lack of full human trials.

Hair loss treatments discussed include alfatradiol, big 3, finasteride, RU58841, and stemoxydine. Alfatradiol is less effective but has fewer side effects, and mixing with stemoxydine may improve results.

The conversation is about how to effectively apply 1mL of a topical hair loss treatment, Pyrilutamide, to cover the entire scalp. One user suggests making a 2.5 mg/mL solution and using 2mL for better coverage.

The user observed that stopping nicotine and caffeine improved their scalp health while using oral finasteride. However, relapsing with caffeine and nicotine caused scalp tightness and inflammation.

The user is considering adding Pyrilutamide or Alfatradiol as a topical treatment for hair loss after oral Finasteride and Dutasteride became less effective. Other users suggest Pyrilutamide for its safety profile, while one user shares positive experiences with RU58841 for reducing scalp itch and improving hairline.

A 44-year-old user experienced hair regrowth using a topical spray combining 0.3% finasteride and 7% minoxidil after switching from oral finasteride due to side effects. The user reported noticeable improvements in hair thickness after four months without any side effects from the topical treatment.

The conversation is about finding a solution for scalp inflammation related to AGA, with the user expressing frustration that Minoxidil and Finasteride do not address inflammation. The user has researched glucocorticoids and topical NSAIDs for reducing inflammation and seeks advice from specialists.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

The user, Virtual_Force3845, shared their progress pictures after using Hims Fin/Min Spray consistently for 3-4 months. They are excited about the progress and have not experienced any side effects. Other users in the conversation shared their own experiences and asked questions about the treatment.

The user is considering switching to oral dutasteride, topical minoxidil, retinoic acid, and clobetasol for hair loss treatment, after limited regrowth with finasteride and other topicals. They are seeking a source for clobetasol, as they believe it may help with their condition.

PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.

The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.

The conversation discusses the potential offering of oral finasteride/dutasteride and oral minoxidil treatments for hair loss, with feedback on pricing and preferences for separate or combined pills. Users express concerns about high costs, preferring affordable options, and some prefer oral over sublingual minoxidil for ease of use.

Considering a switch from finasteride to dutasteride for hair loss treatment, and the use of minoxidil as a last resort due to its effects on hair texture.

The conversation is about the potential cost of GT20029 if FDA approved, with estimates around $150/month. Comparisons are made between GT20029, finasteride, and their mechanisms and side effects.

The user experiences severe side effects from finasteride and dutasteride, including low libido and anxiety, and is currently using oral minoxidil despite shortness of breath. They are seeking alternative treatments for hair loss, having tried pyrilutamide, fluridil, and RU58841 with no success, and are considering future treatments or a hair transplant.

CB-03-01 (Breezula) powder for hair loss. Users discuss its availability and seek feedback on its effectiveness.

Potential treatments for hair loss, specifically the combination of liquid minoxidil and pyrilutamide, with some suggesting that adding finasteride may be beneficial.

The user is considering starting Minoxidil and is looking for a topical solution to combine with it. They are confused about which product to prioritize among options like RU58841, Pyrilutamide, FinaTopic, and DutaTopic.

Exploring treatment options for male pattern baldness, including minoxidil, finasteride, and RU58841, with a focus on Eucapil, a topical agent. The post also discusses research from various sources about the efficacy of these treatments.

A user's positive experience with finasteride for hair loss treatment, and another user's experience with minoxidil. They discuss the potential side effects of finasteride and the success they have had in regrowing baby hairs after several months of use.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

The post discusses using a topical tincture containing zinc, azelaic acid, and other ingredients to inhibit 5 alpha-reductase activity for treating hair loss. The user plans to try this natural alternative before using finasteride or RU58841.

The user is using a 5% minoxidil solution with low propylene glycol and 1 mg of oral finasteride daily but is still experiencing hair shedding, especially at the temples and front. They are concerned about absorption issues and considering adding tretinoin to improve results.